Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1

Conditions

Small Cell Lung Carcinoma 46Lymphoma, Large B-Cell, Diffuse 26Precursor Cell Lymphoblastic Leukemia-Lymphoma 23Leukemia, Myeloid, Acute 20Lung Neoplasms 19Burkitt Lymphoma 18Recurrence 14Lymphoma 14Hodgkin Disease 14Lymphoma, Non-Hodgkin 13Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 10Neuroblastoma 10Lymphoma, Mantle-Cell 10Lymphoma, B-Cell 10Leukemia 10Carcinoma, Non-Small-Cell Lung 10Medulloblastoma 8Neoplasms, Germ Cell and Embryonal 7Neoplasms 7Lymphoma, Follicular 7Multiple Myeloma 6Lymphoma, T-Cell 6Brain Neoplasms 6Sarcoma, Ewing 5Retinoblastoma 5Parkinson Disease 4, Autosomal Dominant Lewy Body 5Immunoblastic Lymphadenopathy 5Ependymoma 5Rhabdomyosarcoma 4Rhabdoid Tumor 4

Interventions

Cytarabine 4venetoclax 2Mitoxantrone 2Daunorubicin 2Cladribine 2thymoglobulin 1quizartinib 1pegylated granulocyte colony-stimulating factor 1fludarabine phosphate 1fludarabine 1blinatumomab 1Transplantation 1Thiotepa 1Tacrolimus 1Sorafenib 1Sirolimus 1Rituximab 1Razoxane 1Mesna 1Melphalan 1Leyk 1Idarubicin 1Granulocyte Colony-Stimulating Factor 1Gemtuzumab 1Filgrastim 1Etoposide 1Dexrazoxane 1Cyclophosphamide 1Bortezomib 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma, Myeloid × Etoposide × 1 year × Clear all
NCT01371981 2026-06-02

Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

National Cancer Institute (NCI)

Phase 3 Completed
1,645 enrolled 32 charts
Other hematologic neoplasmSarcoma

Leukemia, Myeloid, Acute, Sarcoma, Myeloid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡